Answers are grounded in this paper and cite their sources.
Finds genomic alterations related to homologous recombination deficiency in advanced prostate cancer, suggesting implications for precision therapy.
BRCA2-loss CAPC displays a distinct genomic landscape, marked by robust HRD features, suggesting the potential of higher sensitivity to PARPi. These findings highlight the relevance of HRDsig, and routinely use of CGP in refining patient selection for PARPi and guiding the design of future clinical trials.
No takes yet. Share an insight, caveat, or question.
Mercinelli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: